肿瘤细胞治疗研究
英文原题：State-of-the-Art Advancements in Gastroesophageal Cancer Treatment: Harnessing Biomarkers for Precision Care.
State-of-the-Art Advancements in Gastroesophageal Cancer Treatment: Harnessing Biomarkers for Precision Care.
分数与星级只用于站内排序 —— 不代表疗效、安全性或个人适用性。
胃食管癌（GECs）是一项重大的临床挑战。
胃食管癌（GEC）是一项重大的临床挑战。对于早期可切除的GEC，将免疫检查点抑制剂整合到围手术期化疗和放化疗治疗模式中的探索正在进行，并显示出有希望的结果。转移性GEC的一线治疗正在探索PD-1抑制剂之外的靶向治疗的作用，包括抗人表皮生长因子受体2药物、Claudin 18.2抑制剂和FGFR2抑制剂，这些药物在近期试验中显示出相当大的疗效。展望未来，正在进行的试验和新兴技术，如双特异性抗体、抗体-药物偶联物以及过继性细胞疗法如CAR-T 细胞，预计将定义GEC治疗的未来。这些进展标志着向个性化和基于免疫治疗的方法的范式转变，为GEC患者提供了改善预后和降低毒性的潜力。
Gastroesophageal cancers (GECs) represent a significant clinical challenge. For early resectable GEC, the integration of immune checkpoint inhibitors into the perioperative chemotherapy and chemoradiation treatment paradigms are being explored and showing promising results. Frontline management of metastatic GEC is exploring the role of targeted therapies beyond PD-1 inhibitors, including anti-human epidermal growth factor receptor 2 agents, Claudin 18.2 inhibitors, and FGFR2 inhibitors, which have shown considerable efficacy in recent trials. Looking ahead, ongoing trials and emerging technologies such as bispecific antibodies, antibody-drug conjugates, and adoptive cell therapies like chimeric antigen receptor T cells are expected to define the future of GEC management. These advancements signify a paradigm shift toward personalized and immunotherapy-based approaches, offering the potential for improved outcomes and reduced toxicity for patients with GEC.
MEMBER ACCOUNT
登录成功会直接打开下一页。
